Is Krystal Biotech Inc (KRYS) a risky stock?
As of July 25, 2026, Clavix grades Krystal Biotech Inc (KRYS) A for risk, a composite score of 86 out of 100 on an A+ to F scale, which puts KRYS in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 25, 2026. Clavix regrades every trading day.
KRYS price, last 3 months
KRYS's daily closes over the past three months. Clavix reads risk from the fundamentals and news behind the price, not the line itself.
The five risk dimensions behind KRYS's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how KRYS scores on each, as of July 25, 2026.
What's moving KRYS's risk right now
Company-specific signals Clavix flags behind KRYS's current grade, drawn from recent news and filings as of July 25, 2026.
Krystal Biotech will release second-quarter results on August 3. Meanwhile, Tutor Perini is replacing KRYS in the S&P SmallCap 600, and SEB Asset Management disclosed a new 46,343-share stake.
Twelve covering analysts give Krystal Biotech an average price target of $340.56 and a 'Moderate Buy' consensus, with two analysts rating it a Strong Buy.
Recent KRYS news
The latest headlines Clavix ingested for Krystal Biotech Inc, newest first. These feed the news-sentiment dimension of KRYS's grade.
-
Krystal Biotech (KRYS) is highlighted as one of three healthcare stocks outperforming the market year-to-date, driven by strong sales of its only approved product Vyjuvek, a topical gene therapy for dystrophic epidermolysis bullosa (DEB). The company has reported growing revenue and profits, and the article suggests further upside catalysts may sustain momentum.
What a A grade means
On the Clavix A+ to F scale, KRYS's composite of 86 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell KRYS or any security. Grades are risk indicators, not predictions of return. Data may be delayed.